{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T05:12:33Z","timestamp":1737263553129,"version":"3.33.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,17]]},"DOI":"10.7759\/cureus.77602","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T05:41:29Z","timestamp":1737178889000},"source":"Crossref","is-referenced-by-count":0,"title":["Incidence of Thrombotic Complications in COVID-19 Patients and the Impact of Antithrombotic Therapy on ICU Mortality"],"prefix":"10.7759","author":[{"given":"Mohamed F","family":"Hendi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeyad F","family":"Alrais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed I","family":"Shoaib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid M","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sulaiman M","family":"Zaifa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31189-2","article-title":"Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study","volume":"395","author":"Cummings MJ","year":"2020","unstructured":"Cummings MJ, Baldwin MR, Abrams D, et al.. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020, 395:1763-70. 10.1016\/S0140-6736(20)31189-2","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok FA","year":"2020","unstructured":"Klok FA, Kruip MJ, van der Meer NJ, et al.. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020, 191:145-7. 10.1016\/j.thromres.2020.04.013","journal-title":"Thromb Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-021-02475-7","article-title":"Incidence of thrombotic complications in COVID-19: on behalf of ICODE: the International COVID-19 Thrombosis Biomarkers Colloquium","volume":"52","author":"Jenner WJ","year":"2021","unstructured":"Jenner WJ, Gorog DA. Incidence of thrombotic complications in COVID-19: on behalf of ICODE: the International COVID-19 Thrombosis Biomarkers Colloquium. J Thromb Thrombolysis. 2021, 52:999-1006. 10.1007\/s11239-021-02475-7","journal-title":"J Thromb Thrombolysis"},{"key":"ref4","article-title":"Biostatistics 102: quantitative data\u2014parametric & non-parametric tests","volume":"44","author":"Chan YH","year":"2003","unstructured":"Chan YH. Biostatistics 102: quantitative data\u2014parametric & non-parametric tests. Singapore Med J. 2003, 44:391-6.","journal-title":"Singapore Med J"},{"key":"ref5","article-title":"Biostatistics 103: qualitative data - tests of independence","volume":"44","author":"Chan YH","year":"2003","unstructured":"Chan YH. Biostatistics 103: qualitative data - tests of independence. Singapore Med J. 2003, 44:498-503.","journal-title":"Singapore Med J"},{"key":"ref6","article-title":"Biostatistics 104: correlational analysis","volume":"44","author":"Chan YH","year":"2003","unstructured":"Chan YH. Biostatistics 104: correlational analysis. Singapore Med J. 2003, 44:614-9.","journal-title":"Singapore Med J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001628","article-title":"Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review","volume":"8","author":"Matli K","year":"2021","unstructured":"Matli K, Farah R, Maalouf M, Chamoun N, Costanian C, Ghanem G. Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review. Open Heart. 2021, 8:e001628. 10.1136\/openhrt-2021-001628","journal-title":"Open Heart"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18031268","article-title":"Risk management and treatment of coagulation disorders related to COVID-19 infection","volume":"18","author":"Zanza C","year":"2021","unstructured":"Zanza C, Racca F, Longhitano Y, et al.. Risk management and treatment of coagulation disorders related to COVID-19 infection. Int J Environ Res Public Health. 2021, 18:1268. 10.3390\/ijerph18031268","journal-title":"Int J Environ Res Public Health"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12439","article-title":"Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis","volume":"4","author":"Nopp S","year":"2020","unstructured":"Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost. 2020, 4:1178-91. 10.1002\/rth2.12439","journal-title":"Res Pract Thromb Haemost"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005493","article-title":"American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients","volume":"5","author":"Cuker A","year":"2021","unstructured":"Cuker A, Tseng EK, Nieuwlaat R, et al.. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Adv. 2021, 5:3951-9. 10.1182\/bloodadvances.2021005493","journal-title":"Blood Adv"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.04.024","article-title":"Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy","volume":"191","author":"Lodigiani C","year":"2020","unstructured":"Lodigiani C, Iapichino G, Carenzo L, et al.. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020, 191:9-14. 10.1016\/j.thromres.2020.04.024","journal-title":"Thromb Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/1570161119666210824160332","article-title":"Thromboprophylaxis in patients with COVID-19: systematic review of national and international clinical guidance reports","volume":"20","author":"Kyriakoulis KG","year":"2022","unstructured":"Kyriakoulis KG, Kollias A, Kyriakoulis IG, et al.. Thromboprophylaxis in patients with COVID-19: systematic review of national and international clinical guidance reports. Curr Vasc Pharmacol. 2022, 20:96-110. 10.2174\/1570161119666210824160332","journal-title":"Curr Vasc Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11205997","article-title":"Practical recommendations for optimal thromboprophylaxis in patients with COVID-19: a consensus statement based on available clinical trials","volume":"11","author":"Kyriakoulis KG","year":"2022","unstructured":"Kyriakoulis KG, Dimakakos E, Kyriakoulis IG, et al.. Practical recommendations for optimal thromboprophylaxis in patients with COVID-19: a consensus statement based on available clinical trials. J Clin Med. 2022, 11:5997. 10.3390\/jcm11205997","journal-title":"J Clin Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.10.21252749","article-title":"Therapeutic anticoagulation in critically ill patients with COVID-19 - preliminary report. [PREPRINT]","author":"The REMAP-CAP","year":"2021","unstructured":"The REMAP-CAP, ACTIV-4a, ATTACC Investigators, Ryan Zarychanski. Therapeutic anticoagulation in critically ill patients with COVID-19 - preliminary report. [PREPRINT]. MedRxiv. 2021, 10.1101\/2021.03.10.21252749","journal-title":"MedRxiv"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial","volume":"397","author":"Lopes RD","year":"2021","unstructured":"Lopes RD, de Barros E Silva PG, Furtado RH, et al.. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021, 397:2253-63. 10.1016\/S0140-6736(21)01203-4","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15809","article-title":"Good practice statements for antithrombotic therapy in the management of COVID-19: guidance from the SSC of the ISTH","volume":"20","author":"Spyropoulos AC","year":"2022","unstructured":"Spyropoulos AC, Connors JM, Douketis JD, et al.. Good practice statements for antithrombotic therapy in the management of COVID-19: guidance from the SSC of the ISTH. J Thromb Haemost. 2022, 20:2226-36. 10.1111\/jth.15809","journal-title":"J Thromb Haemost"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23605","article-title":"Effect of P2Y12 inhibitors on survival free of organ support among non-critically ill hospitalized patients with COVID-19: a randomized clinical trial","volume":"327","author":"Berger JS","year":"2022","unstructured":"Berger JS, Kornblith LZ, Gong MN, et al.. Effect of P2Y12 inhibitors on survival free of organ support among non-critically ill hospitalized patients with COVID-19: a randomized clinical trial. JAMA. 2022, 327:227-36. 10.1001\/jama.2021.23605","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01825-0","article-title":"Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","author":"RECOVERY Collaborative Group","year":"2022","unstructured":"RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022, 399:143-51. 10.1016\/S0140-6736(21)01825-0","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.2910","article-title":"Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial","volume":"327","author":"Bradbury CA","year":"2022","unstructured":"Bradbury CA, Lawler PR, Stanworth SJ, et al.. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2022, 327:1247-59. 10.1001\/jama.2022.2910","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.17272","article-title":"Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial","volume":"326","author":"Connors JM","year":"2021","unstructured":"Connors JM, Brooks MM, Sciurba FC, et al.. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial. JAMA. 2021, 326:1703-12. 10.1001\/jama.2021.17272","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15808","article-title":"ISTH guidelines for antithrombotic treatment in COVID-19","volume":"20","author":"Schulman S","year":"2022","unstructured":"Schulman S, Sholzberg M, Spyropoulos AC, et al.. ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost. 2022, 20:2214-25. 10.1111\/jth.15808","journal-title":"J Thromb Haemost"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16198","article-title":"Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease","volume":"25","author":"Yuan S","year":"2021","unstructured":"Yuan S, Chen P, Li H, Chen C, Wang F, Wang DW. Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease. J Cell Mol Med. 2021, 25:1263-73. 10.1111\/jcmm.16198","journal-title":"J Cell Mol Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-023-00572-6","article-title":"Association between antithrombotic therapy and mortality in patients hospitalized for COVID\u201119","volume":"22","author":"Wang X","year":"2024","unstructured":"Wang X, Chen W, Guo J, Qiu X, You C, Ma L. Association between antithrombotic therapy and mortality in patients hospitalized for COVID\u201119. Thromb J. 2024, 22:5. 10.1186\/s12959-023-00572-6","journal-title":"Thromb J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104950","article-title":"Enhanced platelet inhibition treatment improves hypoxemia in patients with severe COVID-19 and hypercoagulability. A case control, proof of concept study","volume":"158","author":"Viecca M","year":"2020","unstructured":"Viecca M, Radovanovic D, Forleo GB, Santus P. Enhanced platelet inhibition treatment improves hypoxemia in patients with severe COVID-19 and hypercoagulability. A case control, proof of concept study. Pharmacol Res. 2020, 158:104950. 10.1016\/j.phrs.2020.104950","journal-title":"Pharmacol Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.849628","article-title":"Aspirin in COVID-19: pros and cons","volume":"13","author":"Zareef R","year":"2022","unstructured":"Zareef R, Diab M, Al Saleh T, Makarem A, Younis NK, Bitar F, Arabi M. Aspirin in COVID-19: pros and cons. Front Pharmacol. 2022, 13:849628. 10.3389\/fphar.2022.849628","journal-title":"Front Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/294010-incidence-of-thrombotic-complications-in-covid-19-patients-and-the-impact-of-antithrombotic-therapy-on-icu-mortality","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T05:41:32Z","timestamp":1737178892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/294010-incidence-of-thrombotic-complications-in-covid-19-patients-and-the-impact-of-antithrombotic-therapy-on-icu-mortality"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.77602","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,17]]}}}